Aktuellt
SENASTE
Redeye comments on the conclusion of the phase I part of the ongoing phase I/IIa study of fostroxacitabine bralpamide in liver cancer (HCC). Medivir will not continue with the expansion cohort in the anti-PD-1 arm. We update our Base Case.
LÄS MER
